Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
McKesson
Johnson and Johnson
Dow
Medtronic

Last Updated: January 27, 2023

Details for Patent: 8,470,347


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 8,470,347
Title:Self-emulsifying active substance formulation and use of this formulation
Abstract: The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as dosage form advantageously by use of melt extrusion. The formulations spontaneously form emulsions in water or aqueous media.
Inventor(s): Berndl; Gunther (Herxheim, DE), Breitenbach; Jorg (Mannheim, DE), Heger; Robert (Heidelberg, DE), Stadler; Michael (Neulu.beta.heim, DE), Wilke; Peter (Ludwigshafen, DE), Rosenberg; Jorg (Ellerstadt, DE)
Assignee: AbbVie Deutschland GmbH and Co KG (Wiesbaden, DE)
Application Number:10/296,451
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,470,347
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 8,470,347

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,470,347

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany100 26 698May 30, 2000
PCT Information
PCT FiledMay 29, 2001PCT Application Number:PCT/EP01/06116
PCT Publication Date:December 06, 2001PCT Publication Number: WO01/91727

International Family Members for US Patent 8,470,347

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 344019 See Plans and Pricing
Australia 7963101 See Plans and Pricing
Canada 2408915 See Plans and Pricing
Germany 10026698 See Plans and Pricing
Germany 50111376 See Plans and Pricing
Denmark 1284716 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
McKesson
Dow
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.